High-performance liquid chromatographic analysis of the new antitumour drug SK&F 104864-A (NSC 609699) in plasma.

No abstract is available for this paper.

• Publication year

  1990

• Venue

  Journal of Pharmaceutical and Biomedical Analysis

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/0731-7085(90)80122-6PMID 2100624
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Equilibrium kinetics of the new experimental anti-tumour compound SK&F 104864-A in aqueous solution.

  1990cited by this paper
• Toxicity of camptothecin (NSC-100880).

  1974cited by this paper
• Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies.

  1972cited by this paper
• Plasma camptothecin (NSC-100880) levels during a 5-day course of treatment: relation to dose and toxicity.

  1972cited by this paper

• Handling unstable analytes: literature review and expert panel survey by Japan Bioanalysis Forum Discussion Group.

  2021cites this paper
• Population Pharmacokinetics of Oral Topotecan in Infants and Very Young Children with Brain Tumors Demonstrates a Role of ABCG2 rs4148157 on the Absorption Rate Constant

  2016cites this paper
• Aggregation behavior of anionic surface active ionic liquids with double hydrocarbon chains in aqueous solution: Experimental and theoretical investigations

  2014cites this paper
• Absolute bioavailability studies of a new oral topotecan formulation in Chinese patients using UHPLC-MS/MS.

  2013cites this paper
• Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas.

  2011cites this paper
• Sodium dodecyl sulfate sensitized electrochemical method for sub-picomole level determination of topotecan hydrochloride at a novel disposable electrode

  2011cites this paper
• Phase I Study of Topotecan, Ifosfamide, and Etoposide (TIME) with Autologous Stem Cell Transplant in Refractory Cancer: Pharmacokinetic and Pharmacodynamic Correlates

  2011cites this paper
• Simple liquid chromatography method for the quantification of irinotecan and SN38 in sheep plasma: application to in vivo pharmacokinetics after pulmonary artery chemoembolization using drug eluting beads.

  2010cites this paper
• Phase I Pharmacokinetic and Pharmacodynamic Study of Carboplatin and Topotecan Administered Intravenously Every 28 Days to Patients with Malignant Solid Tumors

  2009cites this paper
• Determination of Belotecan in the Plasma, Bile, and Urine of Rats by High-Performance Liquid Chromatography with Fluorescence Detection and Its Application to a Pharmacokinetic Study

  2009cites this paper
• Clinical pharmacology of camptothecins

  2009cites this paper
• Lack of stability of topotecan in heart tissue homogenates: is it an analytical dilemma or a real phenomenon?

  2009cites this paper
• Application of a highly specific and sensitive fluorescent HPLC method for topotecan lactone in whole blood.

  2009cites this paper
• Safety, pharmacokinetics and pharmacodynamics of targeted anti-cancer drugs

  2009cites this paper
• Rapid Quantification of Topotecan in Biological Samples by Liquid Chromatography/Tandem Mass Spectrometry

  2009cites this paper
• Tolerance and activity of oxaliplatin with protracted topotecan infusion in patients with previously treated ovarian cancer. A phase I study.

  2008cites this paper
• Determination of topotecan in human and mouse plasma and in mouse tissue homogenates by reversed-phase high-performance liquid chromatography.

  2007cites this paper
• Pediatrie Phase I Trial and Pharmacokinetic Study of Topotecan Administered as a 24-Hour Continuous Infusion 1

  2006cites this paper
• Liquid chromatography-mass spectrometry for the quantitative bioanalysis of anticancer drugs.

  2005cites this paper
• High-performance liquid chromatographic assay for the determination of total and free topotecan in the presence and absence of anti-topotecan antibodies in mouse plasma.

  2005cites this paper
• Simple and sensitive high performance liquid chromatographic method for the simultaneous quantitation of the lactone and carboxylate forms of topotecan in human plasma.

  2005cites this paper
• Phase I and Pharmacologic Study of Infusional Topotecan and Carboplatin in Relapsed and Refractory Acute Leukemia

  2005cites this paper
• Phase I and pharmacokinetic study of intraperitoneal topotecan

  2004cites this paper
• Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors

  2004cites this paper
• Topoisomerase I interactive drugs in children with cancer

  2004cites this paper
• Liquid chromatography coupled with tandem mass spectrometry for the quantitative analysis of anticancer drugs in biological matrices

  2004cites this paper
• A Phase I and Pharmacodynamic Study of Fludarabine, Carboplatin, and Topotecan in Patients With Relapsed, Refractory, or High-Risk Acute Leukemia

  2004cites this paper
• Clinical, pharmacokinetic and biological studies of topotecan

  2004cites this paper
• Characterization and application of sodium di(2-ethylhexyl) sulfosuccinate and sodium di(2-ethylhexyl) phosphate surfactants as pseudostationary phases in micellar electrokinetic chromatography.

  2004cites this paper
• Phase I clinical trial of intrathecal topotecan in patients with neoplastic meningitis.

  2003cites this paper
• A phase I and pharmacodynamic study of sequential topotecan and etoposide in patients with relapsed or refractory acute myelogenous and lymphoblastic leukemia.

  2003cites this paper
• Modeling plasma and saliva topotecan concentration time course using a population approach.

  2003cites this paper
• High-performance liquid chromatographic assay with fluorescence detection for the simultaneous measurement of carboxylate and lactone forms of irinotecan and three metabolites in human plasma.

  2003cites this paper
• Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan.

  2002cites this paper
• Phase I Trial of Cisplatin and Topotecan in Children With Recurrent Solid Tumors: Children's Cancer Group Study 0942

  2002cites this paper
• Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors

  2002cites this paper
• Rapid determination of thiamine, riboflavin, pyridoxine, and niacinamide in infant formulas by liquid chromatography.

  2002cites this paper
• No evidence that amifostine influences the plasma pharmacokinetics of topotecan in ovarian cancer patients

  2002cites this paper
• In Vitro pharmacodynamics of CKD-602 in HT-29 cells

  2002cites this paper
• Separation methods for camptothecin and related compounds.

  2001cites this paper
• Analytical approaches for traditional chinese medicines exhibiting antineoplastic activity.

  2001cites this paper
• Antitumor drugs possessing topoisomerase I inhibition: applicable separation methods.

  2001cites this paper
• The effect of increasing topotecan infusion from 30 minutes to 4 hours on the duration of exposure in cerebrospinal fluid.

  2001cites this paper
• Effect of hemodialysis on topotecan disposition in a patient with severe renal dysfunction

  2001cites this paper
• High-Performance liquid chromatographic analysis of lactone and hydroxy acid of new antitumor drug, DX-8951 (exatecan), in mouse plasma.

  2001cites this paper
• Salivary and plasma pharmacokinetics of topotecan in patients with metastatic epithelial ovarian cancer.

  2001cites this paper
• Determination of topotecan by ELISA.

  2001cites this paper
• Phase II and pharmacokinetic/pharmacodynamic trial of sequential topoisomerase I and II inhibition with topotecan and etoposide in advanced non-small-cell lung cancer

  2000cites this paper
• SENSITIVE HIGH PERFORMANCE LIQUID CHROMATOGRAPHIC FLUORESCENCE DETERMINATION OF TOPOTECAN IN HUMAN PLASMA AND PAROTID SALIVA

  2000cites this paper
• Population pharmacokinetic model for topotecan derived from phase I clinical trials.

  2000cites this paper
• Clinical use of topoisomerase I inhibitors in anticancer treatment.

  2000cites this paper
• Population P harmacokinetic M odel f or T opotecan D erived From P hase I C linical T rials

  2000cites this paper
• Determination of camptothecin analogs in biological matrices by high-performance liquid chromatography

  2000influential citation
• Phase I topotecan preparative regimen for high-risk neuroblastoma, high-grade glioma, and refractory/recurrent pediatric solid tumors.

  2000cites this paper
• Cellular and Clinical Pharmacokinetic/Pharmacodynamic Basis for Lack of Efficacy of 21-Day Continuous Topotecan in Patients with Untreated Advanced Adenocarcinoma of the Pancreas

  2000cites this paper
• A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma.

  2000cites this paper
• Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors

  1999cites this paper
• Relationship between tumor extracellular fluid exposure to topotecan and tumor response in human neuroblastoma xenograft and cell lines

  1999cites this paper
• Phase I study of topotecan administered as a 21-day continous infusion in children with recurrent solid tumors: a report from the Children's Cancer Group.

  1999cites this paper
• Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts.

  1999cites this paper
• Reversal of MDR1-associated resistance to topotecan by PAK-200S, a new dihydropyridine analogue, in human cancer cell lines

  1999cites this paper
• Quantification of topotecan and its metabolite N-desmethyltopotecan in human plasma, urine and faeces by high-performance liquid chromatographic methods.

  1999cites this paper
• Activity and pharmacodynamics of 21-Day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. New York Gynecologic Oncology Group.

  1999cites this paper
• Stability and compatibility of topotecan hydrochloride with selected drugs.

  1999cites this paper
• Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma.

  1998cites this paper
• O-glucuronidation, a newly identified metabolic pathway for topotecan and N-desmethyl topotecan.

  1998cites this paper
• Clinical pharmacokinetics of camptothecin topoisomerase I inhibitors.

  1998cites this paper
• Probenecid alters topotecan systemic and renal disposition by inhibiting renal tubular secretion.

  1998influential citation
• A four-hour topotecan infusion achieves cytotoxic exposure throughout the neuraxis in the nonhuman primate model: implications for treatment of children with metastatic medulloblastoma.

  1998cites this paper
• New cytotoxic drugs for intrathecal administration

  1998cites this paper
• Phase II trial of paclitaxel and topotecan with granulocyte colony-stimulating factor support in stage IV breast cancer.

  1998cites this paper
• Phase I trial of the colloidal dispersion formulation of 9-amino-20(S)-camptothecin administered as a 72-hour continuous intravenous infusion.

  1998cites this paper
• Effective schedules of exposure of medulloblastoma and rhabdomyosarcoma xenografts to topotecan correlate with in vitro assays.

  1998cites this paper
• High-performance liquid chromatographic analysis of the investigational anticancer drug 9-aminocamptothecin, as the lactone form and as the total of the lactone and the hydroxycarboxylate forms, in micro-volumes of human plasma.

  1998cites this paper
• Pharmacodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan.

  1998cites this paper
• Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line.

  1998cites this paper
• Isolation and structural confirmation of N-desmethyl topotecan, a metabolite of topotecan

  1997cites this paper
• An overview of the clinical pharmacology of topotecan.

  1997cites this paper
• Plasma pharmacokinetics of 7-ethyl-10-hydroxycamptothecin (SN-38) after intravenous administration of SN-38 and irinotecan (CPT-11) to rats.

  1997cites this paper
• Simple and versatile high-performance liquid chromatographic method for the simultaneous quantitation of the lactone and carboxylate forms of camptothecin anticancer drugs.

  1997cites this paper
• Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic study.

  1997cites this paper
• Cellular pharmacokinetics and cytotoxicity of camptothecin and topotecan at normal and acidic pH.

  1997cites this paper
• Comparison of filter and tunable fluorescence detection for the HPLC simultaneous quantitation of lactone and carboxylate forms of topotecan in plasma

  1997cites this paper
• Pharmacokinetic Optimisation of Cancer Chemotherapy

  1997cites this paper
• Topoisomerase I Inhibitors

  1997cites this paper
• Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedure

  1996cites this paper
• Limited sampling model for area under the concentration time curve of total topotecan.

  1996cites this paper
• Clinical and pharmacological studies on the topoisomerase I inhibitor topotecan

  1996cites this paper
• Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor.

  1996cites this paper
• Clinical Pharmacokinetics of Topotecan

  1996cites this paper
• Sensitive high-performance liquid chromatographic fluorescence assay for the quantitation of topotecan (SKF 104864-A) and its lactone ring-opened product (hydroxy acid) in human plasma and urine.

  1996cites this paper
• The impact of column temperature in the high performance liquid chromatographic analysis of topotecan in rat and dog plasma.

  1996cites this paper
• Escalating systemic exposure of continuous infusion topotecan in children with recurrent acute leukemia.

  1996cites this paper
• Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks

  1995cites this paper
• [Pharmacology of camptothecin and its derivatives].

  1995cites this paper
• High-performance liquid chromatographic determination of the novel antitumour drug topotecan and topotecan as the total of the lactone plus carboxylate forms, in human plasma.

  1995cites this paper
• Determination of GI147211 in human blood by HPLC with fluorescence detection.

  1995cites this paper
• Do topotecan concentrations in saliva reflect plasma concentrations?

  1995cites this paper
• Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion.

  1995cites this paper
• Molecular, cellular, and clinical aspects of the pharmacology of 20(S)camptothecin and its derivatives.

  1995cites this paper